Retrospective study of multiple sclerosis/neuromyelitis optica spectrum disorder patients following infusion of anti-CD20 B-cell depleting therapy
Latest Information Update: 07 Jun 2021
At a glance
- Drugs Ocrelizumab (Primary) ; Rituximab (Primary)
- Indications Multiple sclerosis; Neuromyelitis optica
- Focus Therapeutic Use
- 07 Jun 2021 New trial record
- 22 Apr 2021 Results presented at the 73rd Annual Meeting of the American Academy of Neurology